Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01489865 · ClinicalTrials.gov registry record · Phase 1
ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT01489865 is a Phase 1 study that has completed, run by Georgetown University. The registered enrollment target is 64 participants.
The verdict
NCT01489865, a Phase 1 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxaliplatin) for patients with metastatic pancreatic cancer. ABT-888 inhibits an enzyme called "PARP" which helps to fix damaged DNA. By inhibiting this enzyme, ABT-888 prevents cancer cells from repairing the damage caused by the mFOLFOX-6, and will hopefully increase the killing of cancer cells, thus decreasing the tumors in your body.
Interventions
- DRUG mFOLFOX-6
- DRUG ABT-888
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2011-01-03 |
| Est. Completion | 2023-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01489865
The ClinicalTrials.gov registry entry for NCT01489865 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mFOLFOX-6 is the first listed.
NCT01489865 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01489865 about?
NCT01489865 is a clinical study titled "ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer". People are being asked to participate in this study who have metastatic pancreatic cancer (cancer that has spread to other parts of the body). The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and mFOLFOX-6 (modified 5-Fluorouracil and Oxalipla...
What is the current status of trial NCT01489865?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2011-01-03. Estimated completion is 2023-12-07.
What interventions are being tested in trial NCT01489865?
The interventions under investigation include: mFOLFOX-6 (DRUG), ABT-888 (DRUG).
Who is sponsoring clinical trial NCT01489865?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.